Try our Advanced Search for more refined results
Life Sciences - November, 2012
237 articles
- Ranbaxy Halts Production Of Generic Lipitor
- Sunshine Rule For Physician Payments Moves Forward
- Ex-Penn State Prof. Gets 41 Months For $3M Grant Fraud
- Life Sciences MVP: Covington's John Hurvitz
- Supreme Court Takes Up Appeal Of Post-Mensing Ruling
- High Court Takes Up Myriad Gene Patent Case
- Law360 MVP Awards Go To Legal Top Guns From 52 Firms
- Firm Broke Agreement Over GSK Denture Deal: Kline & Specter
- Takeda Hits Lupin With IP Suit Over Acid Reflux Drug
- 8th Circ. Reverses $1.1M Levaquin Punitive Damages Award
- US Tells High Court Not To Hear Claim Construction Case
- Ex-Takeda Contractor Says New Evidence Revives $6B FCA Suit
- Shire Unit Can't Escape Genzyme False Advertising Suit
- Cosmetics Under Fire: Tips To Avoid FDA Scrutiny
- Highlights Of The New EU Framework For Medical Devices
- Calif. High Court Snubs Price-Fixing Case Against Pfizer, Others
- AstraZeneca Opposes MDL In Nexium Bone Density Suits
- FDA Urged To Give Troubled Compounders A 2nd Look
- 2nd Circ. Backs Another Lilly Win In Zyprexa Warning MDL
- GSK Hit With Suit Over Avodart's Prostate Cancer Risks
- Ex-Baseball Player Indicted For Insider Trading On Abbot Buy
- 8th Circ. Shields Holding Co. From ACA Contraceptive Rule
- St. Jude's Rival Says Co. Flouted Heart Monitor Patent
- Investors Get Class Cert. Over Radient Pharma False Claims
- Bayer Targets Lupin Over Generic Natazia
- How Healthy Is Your Law Firm? Time For A Stress Test
- Nexium Maker Wants Antitrust Claims Handled By Patent Judge
- Lender Wants AstraZeneca Affiliate's Ch. 11 Case Tossed
- Labeling Changes, Not Ban, On Horizon For Energy Drinks
- UK Courts Can Hear Foreign Patent Cases, Judge Rules
- Sidley Austin Nabs Seasoned Ex-FDA Counsel
- NECC Fails To Win Stay In Mass. Meningitis Suits
- Fed. Circ. Won't Rethink Alimta Double Patenting Decision
- Perrigo Settles With Cadence Over Ofirmev Generic Plans
- Mensing Bars Generic Reglan Suits, Drug Cos. Tell Pa. Court
- Stryker, Howmedica To Face Renewed Implant Defect Suit
- Smith & Nephew Pays $782M For Texas Wound Care Co.
- SEC Reportedly Weighing Insider Trading Suit Against SAC
- New ACA Rules Foggy On Drug Coverage, Multistate Plans
- Atty Released From 3M's Defamation Suit After Reaching Deal
- DaVita Hit With FCA Suit Over Alleged Medicare Violations
- FDA Floats State Enforcement Of New Compounder Standards
- Tweaking Brand-Name Drugs Can Hurt Competition, FTC Says
- Texas AG Blasts Subpoena In $421M FCA Suit
- Medtronic Says Off-Label Marketing FCA Claims Fall Short
- BioMimetic Investor Says $380M Buyout Deal Doesn't Cut It
- FDA Says Guidelines On Device Review, Recalls Are Priorities
- Ex-SAC Manager Accused Of Insider Trading Freed On $5M Bail
- DC Circ. Blocks CVS Challenge To DEA License Suspensions
- Mass. Health Panel OKs Free Meals From Drug, Device Makers
- NBTY Nibbles At Health Snack Market With $78M Balance Buy
- GlycoBioSciences Says Skin Ointment Infringed 2 Patents
- Early Steps Toward Developing US Nanopesticide Policy
- Heller Ehrman Skirts $100M Malpractice Claim Over IP Mishap
- Court Limits Contract Claims In Medicare Billing Disputes
- Vitamin C Co. Needn't Yield Audit Docs In Price-Fixing MDL
- Judge Won't Subject All Fosamax MDL Claims To Lone Pine
- FDA Report Faults St. Jude For Handling Of Heart Device
- Pfizer Calls Out Kaiser Over Contradictory Neurontin Claims
- NJ Mulls New Compounding Pharmacy Law Following Outbreak
- FDA's Push For Compounding Oversight Meets Skepticism
- Investors Say Pfizer Destroyed Files On Celebrex, Bextra
- Ignorance Could Be Bliss For SAC's Cohen In Tipping Case
- Eisai Says Zurich Policy Covers Off-Label FCA Suit
- 2nd Circ. Backs Lilly Win In Drug Label Warning MDL
- Millennium Sues Generic-Drug Maker Over Velcade Plans
- Diabetes Test Strip Suppliers Should Expect Audits
- Ob-Gyns Back Over-The-Counter Birth Control Sales
- Norwegian Fish Oil Firm Accepts $847M Offer From BASF
- Illumina Presses $113.3M Bid For DNA Sequencer
- New Drugs, Deals Put Pharma Under Insider Trading Microscope
- Bayer Bows Out Of Bidding War For Schiff Nutrition
- White House Releases ACA Rules On Exchanges, Wellness Plans
- Apotex Targets Exclusivity Period In Generic Benicar Suit
- NECC Ducks Asset Restriction Bid In Meningitis Case For Now
- Pain Therapeutics Can't Duck Investors' Remoxy Suit
- Fed. Circ. Nixes Intema Fetal Test Patent Under Mayo
- High Court To Mull Attys' Fees For Time-Barred Vaccine Claims
- Momenta To Take Generic Lovenox Fight To Supreme Court
- Merck Says High Court Should Hear 2 Pay-For-Delay Cases
- J&J Wants Out Of Ex-Sales Reps' Suit Over Noncompete Deal
- SAC Manager Arrested In $276M Insider Trading Case
- Antitrust Issues Kill $12B Nestle-Pfizer Deal In Mexico
- Judge Won't Revive FCA Medicaid Case Against Allergan, Novo
- A Closer Look At Dietary Supplement Labels
- FDA Gets No Compounder Oversight Without Doc Release: GOP
- Ex-Celgene, Sanofi, Stryker Execs Accused Of Insider Trading
- FDA Moves Up Device ID Deadline For Implantable Devices
- Sidley Austin Lands HHS Counselor For DC Strategies Group
- U of Calif. Wants SNR Off Caldera's X-Ray Licensing Suit
- Pfizer Says Lipitor Buyers Can't Bring Antitrust Challenge
- Wilson Sonsini Aids Wright Medical In $380M BioMimetic Deal
- Takeaways From HHS Corporate Integrity Agreement Reports
- Diagostic Co. Vermillion Escapes Investor Suit
- DOJ May Bring Charges Against FedEx In Online Pharma Probe
- Investors Opt Out Of Pfizer Securities Fraud Class Action
- Takeda Drops Some Infringement Claims In Dexilant Suit
- Investors Sue Heart-Device Co. Over DOJ Mislabeling Fallout
- Boehner Says He's Not Giving Up On ACA Repeal Plans
- 6 Risperdal Suits To See Appeal Over Marketers' Dismissal
- Long-Delayed $45M Becton Antitrust Deal Wins Court OK
- K-V Pharma Wins 3 More Months To File Ch. 11 Plan
- Actavis Tells Judge Purdue's Oxy Patents Rely On Minor Tweak
- Endo Targets Sandoz, Impex Over Generic Versions Of Opana
- Abbott Cert. Bid Says Nixing Pay-For-Delay Will Kill Innovation
- Insurer Can't Pull Coverage For Sorenson Shoulder Pump Suits
- Botox Maker Offers Up To $375M For Fellow Skin Care Co.
- Novartis Loses Fight With USPTO To Extend 19 Patents
- Relators Face Difficulty Pursuing Safety-Based FCA Suits
- 2 Court Rulings Could Lengthen Term Of Many US Patents
- Reckitt Stages Bid War With $1.4B Schiff Buyout Offer
- Diagnostics Co. Shorted Workers On Stock Options, Suit Claims
- Psychiatrist Took Kickbacks From Teva, FCA Suit Says
- Apotex Can Pursue $60M Fee In BMS, Aventis Dispute: Court
- Mutual Makes Last Plea To High Court For Post-Mensing Case
- Senate Slows Down Controversial Cost-Benefit Analysis Bill
- Sanofi Dodges Amphastar's FCA Suit Over Lovenox
- Pfizer Ducks FCA Suit Over Lipitor Marketing Practices
- Compounders Fault FDA For Deadly Meningitis Outbreak
- FDA Approved Possibly Harmful Generic Acetadote, Suit Says
- Dobbs V. Wyeth: Are We There Yet, And At What Cost?
- GSK Pays $90M To Settle States' Claims Over Avandia Risks
- Advantages Of Inter Partes Review In Hatch-Waxman Cases
- Edwards Wins Invalidity Ruling In Medtronic Patent Row
- Ruling Puts Drug Cos. In Prime Position To Avert State Court
- Zimmer Must Face Most Of Stryker Poaching, Trade Secrets Suit
- House Reps. Want New Health Care Panel To Repeal ACA
- Pernix Inks $101M Deal To Purchase Cypress Pharmaceuticals
- Cumberland Settles 2 Patent Suits Over Generic Acetadote
- Pa. High Court Stifles Appeal In Orthopedics Kickback Suit
- What To Expect From Fungal Meningitis Liability Cases
- FDA Wants Strong Authority Over 'Nontraditional' Compounders
- GE, Cardinal Say Imaging Drug Antitrust Claims Lack Specifics
- German Court Voids AstraZeneca's Seroquel XR Patent
- Medtronic Targeted Over Surgery Imaging Patent
- FDA Marketing Rules Stretch To Drugmakers' Media Pitches
- FDA To Seek More Power Over Compounders At Hearing
- Watson Calls On High Court To Support 'Pay-For-Delay' Deals
- Alnylam Puts Up $65M To End Tekmira Trade Secrets Battle
- SEC Can Use SOX To Claw Back Exec Bonuses, Judge Rules
- Fed. Circ. Affirms $74M Edwards Award In Catheter IP Row
- Divergent Views Of Patent Eligibility Give Little Insight
- Relocation Steps For Wireless Medical Telemetry Users
- Ex-Cephalon GC Joins Cozen O'Connor
- Merck Sues Fresenius To Block Integrilin Generic
- K-V's Makena ITC Suit Would Create Monopoly, Pharmacies Say
- Pfizer Pays $67.5M To End Investors' Pristiq Disclosure Row
- Tips For Quality Control In Technology-Assisted Review
- Ex-Boston Scientific Worker Followed Noncompete, Judge Says
- Coalition Floats Ways To Save Medicare Payments From Cuts
- Q-Med Says $3B Medicis-Valeant Deal Violates Licensing Pact
- Abbott Slaps Watson With Patent Suit Over Niaspan Generic
- Baxter Recalls Buretrol IV Products Over Air Leakage Risk
- FDA Panel Backs Novo Diabetes Drugs, With Conditions
- Arnold & Porter Adds Life Sciences Pro From Biopharma Firm
- AstraZeneca Sues To Block Lupin's Generic Seroquel XR
- The Case For Compounding Pharmacy
- Royal DSM Pays $634M For Nutrient Maker Fortitech
- Buchanan Ingersoll Hires Connolly Bove Pharma IP Atty
- Mylan, J&J Unit Reach Deal In Birth Control Drug Patent Row
- Medical Device Makers Urge FDA To Narrow ID Rule
- Humana Failed To Monitor Drug Refills, HHS Report Says
- Apotex Urges High Court To Nix 'Lead Compound' Patent Test
- Pfizer, Wyeth Lose 3rd Circ. Bid To Toss Pa. Fen-Phen Suit
- Bayer Healthcare Hit With More Mirena Product Defect Suits
- Boston Scientific To Pay Up To $425M For Catheter Maker
- Canada's High Court Kills Viagra Patent In Pfizer-Teva Row
- Missing The Class Action Removal Boat To Federal Court
- Former Chem Rx Execs Dodge Trustee's Suit Over 2007 Buyout
- Judge's Rebuke Of USPTO Paves Way For Longer Patent Terms
- NJ High Court Won't Disturb Novartis Bone Drug Win
- Mass. Official Fired For Ignoring Compounding Center Concerns
- Ex-Guidant Rep. Asks 1st Circ. To Revive Pacemaker FCA Suit
- FTC Resolves Price-Fixing Claims Against Pharmacy Group
- Skelaxin Pay-For-Delay Battle Heads To Pa. State Court
- KV Pharma, Ill. End Medicaid Coverage Dispute Over Makena
- FDA Won't Pull Pfizer Alzheimer's Drug From Market
- Inventions In Unpredictable Fields — Not Always Unobvious
- Qualitest Beats Class Cert. Bid In Birth Control Recall Suit
- FDA Tells DC Circ. It Can't Review Execution Drug Ban
- Dexatrim Maker Beats Suit Alleging Pills Are Unsafe
- Transitions Must Produce FTC Probe Docs, Judge Rules
- Cephalon Urges Fed. Circ. To Revive Fentora Patents
- DOJ Probes Novartis Ties With Specialty Pharmacies
- Takeda Pays $140M To Snap Up Envoy Therapeutics
- Pharmacy Owner Subpoenaed To Testify On Meningitis Outbreak
- Pepper Hamilton Adds Nutter McClennen IP Attorneys
- Novo's Proposed Insulin Drugs Could Pose Risks, FDA Says
- FDA Says Co. Is Trying To Cash In On Meningitis Outbreak
- Citing Sandy, Quigley Seeks More Voting Time For Ch. 11 Plan
- Equistone Buys Sunrise's Wheelchair Division From Vestar
- What Obama's Re-Election Means For Health Care Policy
- Obama's Tough-Minded FDA Faces Funding Test
- Obama Win Promises Heightened Push For Product Safety
- Amgen Tells High Court Investor Class Hinges On Materiality
- FDA Head To Talk Compounder Oversight In Meningitis Hearing
- Myriad Tells Justices To Reject ACLU Gene Patent Challenge
- Novartis Smacked With $10.5M Verdict In Jaw Injury Suit
- A Clarification Of Obviousness-Type Double Patenting
- Ex-Bayer Salesman Wins Award In FCA Retaliation Suit
- Six More Women Join $100M Forest Labs Bias Case
- FDA Approval Can't Nix Allergan Patent Obviousness: Sandoz
- Crisis Management From The Board's Perspective
- Novartis Bone Drug Appeal Won't Get High Court Review
- Hydroxycut Consumers Reach $25M Deal In False Ad MDL
- Atty Must Provide $40M Fen-Phen Deal Info To US: 6th Circ.
- Top 9 Questions About Prop 37
- Pfizer Reports $491M Deal With DOJ Over Rapamune Marketing
- Markey's Post-Outbreak Bill May Fall Short Of Desired Overhaul
- High Court Asked To Reject Appeal Of Post-Mensing Ruling
- J&J Wins Bid To Keep Children's Tylenol Suit In Fed. Court
- Mylan Says Cephalon's Patent Win Could Make Generics Scarce
- Chattem Offers Up To $1.5M To End Mouthwash Suit
- Fed. Circ. Says Woman Didn't Show Vaccine Caused Injury
- UniQure's Glybera 1st Gene Therapy Approved In EU
- How The Presidential Election Could Curtail ADA Regs
- Orthofix Division To Pay $30M To End FCA Kickbacks Suit
- A Twist On Disclosure-Based Shareholder Suits
- Omeros Pays $4M To End Whistleblower's FCA Suit
- DOJ Wants Teva Docs In Connection With FCPA Investigation
- Wal-Mart Beats False Ad Suit Over Joint Health Supplement
- Judge Won't Block Ex-Stryker Exec From Jumping To Zimmer
- Merck Puts Up $39M To Settle Vioxx Class Action
- Gov't Won't Contest Bid To Revive Religious ACA Challenge
- Takeda Escapes FCA Suit Over Undisclosed Drug Complications
- Markey Rolls Out Reform Bill In Wake Of Meningitis Outbreak
- Enzo Wins $49M Verdict In DNA Labeling Patent Row
- J&J Close To Settlement With 845 Plaintiffs In Levaquin MDL
- Top Medical Journal Demands More Trial Data From Drug Cos.
- PhRMA Urges FTC Not To Expand Patent Licensing Scrutiny
- Acura Targets 4 Rivals Over Generic Oxecta Plans
- Fidelity PE Arm Invests $74M In Indian Health Care Co.
- Ex-FDA Head To Testify In GSK Flonase Antitrust Row
- Medtronic Stents Infringe 2 Patents, Suit Alleges
- Johns Hopkins Says Life Technologies Flouts Gene Test IP
- Reversing USPTO Appellate Board Ruling: Not An Easy Task
- Mapping The Pre-Election Landscape